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Abstract
To date, there are no phase III trial data that can guide healthcare professionals in managing toxicities of epidermal growth factor receptor 
inhibitors (EGFRIs). This exploratory survey assessed the similarities and differences in nursing management of EGFRI-related toxicities 
across 10 European countries. A questionnaire that was sent to ten nurses who specialize in the treatment of patients with EGFRI asked 
about the prevention and treatment of acneiform rash, dry skin/eczema, fissures, paronychia, and pyogenic granuloma. Responses from 
seven nurses showed that overall (with the exception of rash), treatment differed markedly between countries in the management of der-
matologic toxicities. These substantial differences across the European hospitals surveyed suggest that it might be worthwhile to develop 
treatment algorithms by conducting a consensus conference or a follow-up survey with several assessments and a larger sample. 
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Cancer treatment is being transformed with the advent of entirely new classes of drugs that specifically inhibit genes, proteins, or proc-
esses involved in cancer development, thus sparing a greater number of healthy cells. One cancer drug target is the epidermal growth 
factor receptor (EGFR, also called ErbB1 and human epidermal growth factor receptor 1 (HER 1)). EGFR is a member of a protein 
family called receptor tyrosine kinases, which control vital cell processes such as proliferation, migration, and survival [1]. EGFR has 
been linked to many common cancers, including head and neck cancer, colorectal cancer (CRC), pancreatic cancer, and non-small-
cell lung cancer (NSCLC), and overproduction of EGFR is associated with more aggressive clinical behavior (including more tumor 
angiogenesis, proliferation, and metastasis) and shorter overall survival time [2–4]. Based on their efficacy in clinical trials, therapies 
that inhibit the EGFR signaling pathway, such as the small-molecule inhibitors, erlotinib (Tarceva®) and gefitinib (Iressa®), and the 
monoclonal antibodies, cetuximab (Erbitux®) and panitumumab (Vectibix®), are now routinely used in clinical practice to control these 
cancers [5–8].
Several types of epithelial cells, such as those in the epidermis, hair follicles, sebaceous glands, mucosal tissues, and ocular tissues, 
produce high levels of EGFR. Epidermal growth factor receptor inhibitors (EGFRIs) are thus commonly associated with class-specific 
toxicities, many of which are new to oncology teams and differ from the toxicities regularly observed with conventional chemotherapy 
regimens [9]. Skin toxicities, such as acneiform rash, dry skin, fissures, and nail and hair disorders, are commonly associated with treat-
ment with EGFRIs [10,11]. To date, there are no data from phase III trials that can guide healthcare professionals in managing toxicities 
of EGFRIs.
In this article, a first step towards improving and standardizing patient care is reported. In brief, an exploratory survey of nurses from 
different European countries was conducted to assess the similarities and differences in the management of EGFRI-related toxicities 
across European countries. Between April and November 2009, a questionnaire was sent to ten hospital-based clinical nurse specialists 
who focus on the treatment of patients with EGFRI; these nurses were selected based on their prior participation in a nursing advisory 
board on skin toxicities of EGFRIs or membership in the European Oncology Nursing Society TARGET task force on targeted therapies. 
The questionnaire asked about the prevention and treatment of EGFRI-related dermatologic toxicities including acneiform rash, dry skin/
eczema, fissures, nail changes such as paronychia, and pyogenic granuloma. All questions were open-ended to allow for the possibil-
ity of discovering management approaches that are not reported in the literature. Seven nurses responded, from Belgium, Ireland, the 
Netherlands, Spain, Sweden, Switzerland and the United Kingdom. As shown in the tables and discussed in detail below, approaches to 
management of EGFRI toxicities differed substantially across the nurses surveyed.
Skin rash
All survey respondents provided patient education and general skin care advice, including the use of moisturizers (Table 1), but they also 
reported that they do not provide routine pharmaceutical prophylaxis for skin rash. In some countries, topical antibiotic creams are given 
immediately with the appearance of grade 1 acneiform rash, while in others oral antibiotics are preferred. Treatment of grade 3 acneiform 
rash varies greatly, with oral/topical steroids as well as antibiotics and antihistamines being incorporated into some strategies. Overall, 
there appeared to be substantial variation in the management of skin toxicities across Europe. These results are consistent with another 
survey that inquired about the management of EGFRI-associated skin rash across 110 oncology practices in the United States, which also 
detected pronounced diversity in the types of interventions used [12].
An interdisciplinary, international panel has recommended dividing papulopustular reactions into three categories, based on the sever-
ity of symptoms, the impact of symptoms on daily activities, and whether the patient has signs of, or potential for, superinfection [13,14]. 
According to the international guidelines, if there is no response to rash treatment within 2—4 weeks, EGFRI therapy should be temporar-
ily suspended as directed by the manufacturer [13,14]. Therapy can be restarted once the rash adequately diminishes in severity. Referral 
to a dermatologist is warranted if lesions have an uncharacteristic appearance or distribution; if there is necrosis, blistering, or petechial/
purpuric lesions; or if patients have atypical dermatological manifestations unrelated to rash [15]. However, consistent with the findings of 
this survey, all recommendations are based on experience rather than clinical trial data, and there are important geographic variations in 
actual management of EGFRI skin toxicity [11].www.ecancermedicalscience.com 3
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Table 1: Prevention and treatment of acneiform rash
Country
Prevention/
prophylaxis Grade 1 Grade 2 Grade 3 Grade 4
Other 
treatment
Belgium Patient education; 
skin care starter 
set (if available 
from EGFRI 
manufacturer).
Use skin 
cleansing; 
moisturizing 
cream; further 
self-care 
instruction; if 
needed, oral 
minocycline 100 
mg/day in evening.
As for grade 
1, except give 
minocycline 200 
mg/day in evening, 
depending on 
patient need and 
severity of rash.
As for grade 1, 
except give 200 mg 
minocycline. For 
superinfection, add 
other antibiotics. 
For pruritus, add 
analgesic and/or 
antihistamine.
Not seen yet. No response.
Ireland Use moisturizing 
cream (water-based) 
on limbs, hands, 
and feet. Avoid sun 
(wear protective 
clothes). Use 
sunblock SPF 35.
Use metronidazole 
cream twice daily.
As for grade 
1, except add 
minocycline 100 
mg/day. For itching, 
add antihistamine.
Use metronidazole 
cream up to 5 times 
daily, minocycline 
100 mg/day 
(increased to 200 
mg/day if required), 
saline compresses 
15 min twice daily. 
For itching, add 
antihistamine. 
For S. aureus 
superinfection, add 
broad-spectrum 
antibiotics. If no 
response, consider 
dose-adjusting or 
interrupting EGFRI.
No guidelines. No response.
The Netherlands Moisturize skin 
twice daily with a 
neutral cream on 
the entire body. Use 
sun protection; take 
short showers, no 
soap.
Use metronidazole 
cream 1%–2% 
100 mg twice 
daily. If no 
improvement after 
2 weeks, increase 
to 200 mg.
As for grade 1, with 
or without additional 
oral steroids.
As for grade 1, plus 
oral steroids. If no 
improvement after 2 
weeks, EGFRI dose 
delay or reduction.
Not seen yet. 
Grade 4 is rare.
No response.
Spain Advise patients to 
moisturize dry areas 
of the body twice 
a day (e.g. using a 
thick alcohol-free 
emollient). Minimize 
exposure to sunlight 
and use broad-
spectrum sunscreen 
(SPF > 15).
Use topical 
hydrocortisone 
(1% or 2.5%) and 
clindamycin 1% 
gel.
As for grade 1, plus 
tetracycline oral 
antibiotics and oral 
antihistamine for 
itch.
As for grade 2. 
Consider involving 
dermatologist.
As for grade 
3. Consider 
intravenous 
antibiotic and 
a culture to 
determine 
bacterial strain 
if antibiotic 
resistance is 
suspected.
Avoid acne 
vulgaris 
medications 
as these 
treatments 
could irritate 
and worsen the 
skin rash.
Sweden Patient education, 
written guidelines.
Employ local 
treatment, 
take systemic 
treatment into 
consideration.
Employ local and/or 
systemic treatment.
Employ systemic 
treatment. 
Consider EGFRI 
dose reduction or 
interruption.
Employ systemic 
treatment. Refer 
to skin specialist. 
Interrupt EGFRI.
There is a 
special list 
of creams, 
ointments, and 
drugs that must 
be used with 
different grades.ecancer 2011, 5:220
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Dry skin
Various approaches to preventing dry skin were recommended, but the use of emollients and protection against the sun were among the 
most common (Table 2). Management approaches differed from each other with regard to the types of emollients to be used; whether and 
when to use corticosteroids; and the need for, and timing of, referral to a dermatologist. Not all respondents mentioned examining patients 
for the possibility of infection, although it could be assumed that these evaluations are conducted when infections are suspected.
Fissures
For fissures, there was virtually no overlap in the therapeutic measures reported, although two respondents reported using propylene glycol 
for grade 1 fissures. Four respondents reported giving pain medication, but the timing of its initiation varied. Only two respondents reported 
experience with grade 4 fissures. In one of these centers reduced dose or interrupted EGFRI therapy for severe fissures. Common recom-
mendations for the treatment of fissures in Europe include a 50% solution of propylene glycol in water, an ointment containing 10% salicylic 
acid, or a hydrocolloid dressing or liquid cyanoacrylate glue [11]. Patient education also differed widely among the respondents, according 
to whether prophylactic care is recommended for the entire body, just the hands and feet, just the hands, or just the feet (see Table 3).
Paronychia
Treatment of paronychia among the respondents varied even more markedly than treatment of the other dermatologic toxicities (see 
Table 4). For grade 1 paronychia, management strategies ranged from observation to the use of an oral antibiotic. Most respondents gave 
some sort of topical treatment for grade 1; two added a corticosteroid for grade 3. Antibiotic therapy was given if needed. Three respond-
ents considered referral to a dermatologist for moderate or severe paronychia. Only two respondents reported experience with grade 4 
paronychia; EGFRI therapy was routinely stopped for grade 4 paronychia at one of the centers.
Pyogenic granuloma
Only three respondents reported experience with any grade of pyogenic granulomas because this condition is rarely observed (see 
Table 5). One nurse felt that no effective treatment was available for this condition. For grade 1 pyogenic granulomas, the three respondents 
Switzerland Usually no 
prophylactics are 
used. Provide 
patient education. 
Use skin care starter 
set (from EGFRI 
manufacturer); 
content is optimized 
according to hospital 
practice.
Phase I: Cleanse skin, use moisturizing cream, give further 
instruction for self-care.
Phase II: Possibly begin antibiotics, depending on patient need 
and severity of rash.
Phase III: Begin antibiotic, often clindamycin; corticosteroid 
cream depending on patient need and severity of rash.
Not seen yet. No response.
United Kingdom None. Use topical 
clindamycin.
Add oral antibiotic, 
‘Wyamycin’ or 
minocycline.
Dose-reduce 
EGFRI; 
hydroxyzine; 
dermal lotion and 
‘Betnovate’ scalp 
application.
Stop EGFRI. No response.
EGFRI, epidermal growth factor receptor inhibitor; SPF, sun protection factor.www.ecancermedicalscience.com 5
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recommended various antiseptic soaks; they recommended adding topical treatment and oral antibiotics (if superinfections were present) 
for grade 2. A short course of nonsteroidal anti-inflammatory drugs was also suggested to alleviate pain. For prophylactic care, three 
nurses advised patients to moisturize their bodies twice daily with an alcohol-free emollient and to minimize exposure to the sun or use 
broad-spectrum sun protection. One nurse also recommended that patients take short showers without soap.
Country Prevention/prophylaxis Grade 1 Grade 2 Grade 3 Grade 4
Other 
treatment
Belgium Instruct patients to use 
moisturizers without high 
fat content.
Use emollients. Use strong emollients. 
For dry eczema, use 
corticosteroid cream 
(1–2 weeks). For wet, 
superinfected eczema, 
use topical fusidic acid 
+ antibiotics (5–10 
days).
Use emollients. 
Some short 
use of steroids/
antibiotics in 
case of infection.
Not seen yet. No response.
Ireland Use mild soaps, avoid 
harsh laundry detergents, 
use tepid water when 
showering or bathing.
Use emollients. 
For eczema, 
use weak topical 
corticosteroids, 
‘Modrasone’ 
ointment.
As for grade 1; if 
superinfected, add 
antibiotics.
Not seen yet. Not seen yet. No response.
The 
Netherlands
Moisturize skin twice 
daily with a neutral cream 
on the entire body. Use 
sun protection; take short 
showers, no soap.
Use 20% white 
paraffin in 
cetomacrogol 
cream.
Use an oral antihistamine (hydroxyzine 
or cetirizine); for eczema, intermittent 
corticosteroid: fluticasone cream 0.5 mg/g 
(‘Cutivate’) or betamethasone cream 1 mg/g 
(‘Betnelan’) 7–14 days.
Not seen yet. No response.
Spain Advise patients to 
moisturize dry areas of 
the body twice a day (e.g. 
using a thick alcohol-
free emollient). Minimize 
exposure to sunlight and 
use broad-spectrum 
sunscreen (SPF > 15).
Use topical 
hydrocortisone 
(1% or 2.5%) and 
clindamycin 1% 
gel.
As for grade 1, plus 
tetracycline oral 
antibiotics and oral 
antihistamine for itch. 
Consider involving 
dermatologist.
Not seen yet. Not seen yet. No response
Sweden Provide patient 
education, adhere to 
written guidelines.
Observe if 
asymptomatic, 
use steroid 
creams if 
symptomatic.
As for grade 1. Use ‘soft 
creams.’
As for grades 1 
and 2. Employ 
local treatment.
As for grade 3. 
Consult skin 
specialist.
There is a 
special list 
of creams, 
ointments, and 
drugs that must 
be used with 
different grades.
Switzerland Instruct patient to use 
moisturizers without high 
fat content.
Use emollients 
with urea.
As for grade 1. As for grade 
1. Some use 
of steroids if 
dermatologist 
suggests.
Not seen yet. No response.
United 
Kingdom
None. Use ‘Diprobase’. Use ‘Oilatum’ bath salts 
and lotion.
Refer to 
dermatologist.
Refer to 
dermatologist.
‘E45 cream’.
EGFRI, epidermal growth factor receptor inhibitor; SPF, sun protection factor.
Table 2: Prevention and treatment of dry skin/eczemaecancer 2011, 5:220
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Country
Prevention/
prophylaxis Grade 1 Grade 2 Grade 3 Grade 4 Other treatment
Belgium Use emollient cream 
several times a day 
(after hand wash). Take 
off shoes.
Use hand cream, 
‘Fucidin’ crème, 
cover fissures in 
evening.
Use hand cream. 
For open fissures, 
‘Fucidin.’ Use 
propylene glycol 
50% aqueous 
solution under plastic 
occlusion (30 min/
day), salicylic acid 
10% ointment, 
hydrocolloid 
dressing.
Use emollients 
with urea. Cover 
open fissures 
with propylene 
glycol three times 
daily, after that 
use emollients 
or ‘Fucidin’ with 
bandage. Use 
systemic pain 
medication if 
necessary.
Not seen 
yet.
Use of fine cotton 
gloves while working 
and during night 
time. Patients are 
very inventive; they 
experiment with lots of 
different creams and 
bandages.
Ireland Avoid tight shoes. Use propylene glycol 40% in aqueous cream with 2% salicylic 
acid twice daily.
Not seen 
yet.
No response.
The 
Netherlands
Moisturize skin 
twice daily with a 
neutral cream on the 
entire body. Use sun 
protection, take short 
showers, no soap.
Use 50% 
propylene glycol 
in cetomacrogol 
cream.
As for grade 1; use 
paracetamol or 
ibuprofen.
Not seen yet. Not seen 
yet.
No response.
Spain Keeps hands dry and 
out of water as much as 
possible, or use gloves.
Consider topical 
antiseptics such 
as topical silver 
and topical 
hydrocortisone 
(1% or 2.5%) and 
clindamycin 1% 
gel.
Consider involving 
dermatologist.
Not seen yet. Not seen 
yet.
To reduce pain, 
redness and swelling, 
consider a short 
course of an NSAID 
(e.g. 400 mg ibuprofen 
2–3 times/day).
Sweden Provide patient 
education, adhere to 
written guidelines.
Use ‘Alsolsprit’ 
compress.
As for grade 1 plus 
‘Betnovate’ with 
chinoform if needed.
As for grade 2 plus 
culture and oral 
antibiotics.
As for 
grade 3.
No response.
Switzerland Use emollient cream 
twice daily on hands and 
feet.
Use emollients 
with urea; 
examine painful 
areas for open 
wound.
Use emollients 
with urea, protect 
open fissures with 
‘Fingerrisse’ bandage 
or according to 
patient preference.
As for grade 2. Not seen 
yet.
Use fine cotton gloves 
while working.
United 
Kingdom
None. Use ‘DiproBase’ 
cream.
Pyridoxine. Increase dose of 
pyridoxine and 
reduce EGFRI 
dose.
Stop 
EGFRI 
drug.
Use antibiotic 
ointments.
EGFRI, epidermal growth factor receptor inhibitor; NSAID, nonsteroidal anti-inflammatory drug.
Table 3: Prevention and treatment of fissureswww.ecancermedicalscience.com 7
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Conclusion
This pilot survey of European hospitals revealed that there is no consensus on the management of EGFRI-related skin toxicities, but 
respondents clearly agreed that these toxicities need treatment. This is not surprising, given that treatment options described in the medi-
cal literature are based on case reports, case series, or reported personal experience, not on data from large, randomized, controlled 
trials. Other potential explanations for differences in management are that (a) the specific approved EGFRIs and their indications vary 
between countries in Europe and (b) different agents have slightly different toxicity profiles.
Despite the diversity in their answers, the respondents clearly recognized that EGFRI toxicities are treatable and require medical interven-
tion. While dermatologic reactions are usually mild to moderate in severity, they are sometimes physically or emotionally bothersome such 
Country Prevention/prophylaxis Grade 1 Grade 2 Grade 3 Grade 4 Other treatment
Belgium Educate patient that this 
may occur.
No response. Rinse with local antiseptic; 
individualized decision for antibiotics. 
Protect fingertips according to patient 
preference.
Not seen 
yet.
No response.
Ireland No response. Use antiseptic soaks 
twice a day (e.g. one 
part vinegar to ten 
parts water for 5 min 
each time).
As for grade 1 plus 
‘Lotriderm’ cream. 
For superinfection, 
give broad-spectrum 
antibiotics. If skin is 
oozing, take a swab.
As for grade 2, 
plus NSAIDs 
to control pain.
Not seen 
yet.
No response.
The 
Netherlands
Moisturize skin twice daily 
with a neutral cream on 
the entire body. Use sun 
protection; take short 
showers, no soap.
Use silver nitrate 
applicators (75% silver 
nitrate, 25% potassium 
nitrate) once daily.
As for grade 1, plus high-class 
corticosteroid (clobetasol cream 0.5 
mg/g (‘Dermovate’), minocycline, or 
doxycycline 100 mg/day). For infection, 
give flucloxacillin 3 × 500 mg/day for 7 
days.
Not seen 
yet.
No response.
Spain Keeps hands dry and out of 
water as much as possible, 
or use gloves. Avoid too-
tight shoes, to prevent 
friction on the nail.
Try frequent 
applications of topical 
petrolatum around 
nails. Consider topical 
antiseptic and/or topical 
antibiotic.
Try topical steroid 
2–3 times/day. Oral 
antibiotic must be 
considered if a 
bacterial infection is 
suspected. Consider 
culturing and involve 
dermatologist.
Not seen yet. Not seen 
yet.
To reduce pain, 
consider a short 
course of an 
NSAID (e.g. 400 
mg ibuprofen 
2–3 times/day).
Sweden Provide patient education, 
adhere to written 
guidelines.
Use ‘Alsolsprit’ 
compress.
Cultures; with 
infection, give oral 
antibiotics.
As for grade 
2; consider 
referral to skin 
specialist.
As for grade 
3.
No response.
Switzerland Educate patient that this 
may occur.
No therapy is needed in 
the absence of lesions.
Rinse with local antiseptic; 
individualized decision for antibiotics. 
Protect fingertips according to patient 
preference.
Not seen 
yet.
No response.
United 
Kingdom
None. Give oral 
antibiotic—flucloxacillin.
Add penicillin V. Refer to 
dermatologist.
Stop EGFRI. No response.
EGFRI, epidermal growth factor receptor inhibitor; NSAID, nonsteroidal anti-inflammatory drug.
Table 4: Prevention and treatment of paronychiaecancer 2011, 5:220
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that patients wish to discontinue therapy. Conversely, patients may under-report their symptoms out of fear that the anticancer therapy 
will be withheld. Therefore, it is important that healthcare professionals minimize the incidence and severity of side effects, prevent their 
progression, and thus the need for dose reduction or discontinuation of potentially effective treatment.
Standardized consensus guidelines to prevent or treat EGFRI-related dermatologic toxicities may help improve patient care and be a 
useful resource for clinicians throughout Europe. These guidelines should include detailed information on how to educate patients about 
lifestyle modifications, early signs of toxicity, and the importance of treatment adherence; how to regularly assess patients’ side effects 
and related quality of life; and how to provide resources for psychosocial support. Assessment or patient self-report of side effects should 
begin within 14 days from EGFRI initiation [7].
This survey was exploratory, and the results should be interpreted in the context of certain limitations. The survey is not representative 
of the entire European Union or of all hospitals within each country. A more detailed follow-up survey with an expanded questionnaire 
is planned in order to facilitate the development of a consensus statement and, potentially, algorithms for the optimal treatment of toxici-
ties. In the meantime, management of EGFRI-related toxicities should be undertaken on a case-by-case basis, with an emphasis on 
Country Prevention/Prophylaxis Grade 1 Grade 2 Grade 3 Grade 4
Other 
Treatment
Belgium Patient education that this 
may occur.
No ‘effective’ treatment. Use antiseptic (chloramine, povidon iodine), 
NSAID to control pain, drying paste and antiseptic (chlorhexidine), or 
silver nitrate weekly. For superinfection, use oral antibiotics. Partial or 
total nail extraction may be necessary.
No 
response.
No response.
Ireland No response. Use antiseptic soaks 
twice a day (e.g. one 
part vinegar to ten 
parts water for 5 min 
each time).
As for grade 1 plus 
betamethasone 
diproprionate/ clotrimazole 
cream. For superinfection, 
use broad-spectrum 
antibiotics. If skin is 
oozing, take a swab.
As for grade 2, 
plus NSAIDs to 
control pain.
Not seen 
yet.
No response.
The 
Netherlands
Moisturize skin twice daily 
with a neutral cream on 
the entire body. Use sun 
protection. Take short 
showers without soap.
No response. No 
response.
No response.
Spain Advise patients to 
moisturize dry areas of the 
body twice a day (e.g. thick 
alcohol-free emollient). 
Minimize exposure to 
sunlight and use broad-
spectrum sunscreen (SPF 
> 15).
Use a topical 
antiseptic such as 
topical silver nitrate 
weekly.
Oral antibiotics combined 
with topical treatment. 
Consider involving 
dermatologist and/or 
surgeon.
Not seen yet. Not seen 
yet
To reduce pain, 
consider a 
short course of 
an NSAID (e.g. 
400 mg 2–3 
times/day).
Sweden No response.
Switzerland No response. Not seen yet. No response.
United 
Kingdom
No response. Not seen yet. No response.
EGFRI, epidermal growth factor receptor inhibitor; NSAID, nonsteroidal anti-inflammatory drug; SPF, sun protection factor.
Table 5: Prevention and treatment of pyogenic granulomawww.ecancermedicalscience.com 9
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  preventing dose modification whenever possible. Effective management and patient education may help to alleviate the significant social 
and emotional anxiety related to these manageable toxicities, thus resulting in improved quality of life.
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